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Abstract
Background: Despite intensive research over the last several decades on prostate cancer, many
questions particularly those concerning early diagnosis and the choice of optimal treatment for
each individual patient, still remain unanswered. The goal of treating patients with localized prostate
cancer is a curative one and includes minimizing adverse effects to preserve an adequate quality of
life. Better understanding on how the quality of life is affected depending on the treatment modality
would assist patients in deciding which treatment to choose; furthermore, the development of
prognostic biomarkers that indicate the future course of the illness is a promising approach with
potential and the focus of much attention. These questions can be addressed in the context of a
cohort study.
Methods/Design: This is a prospective, multi-center cohort study within the canton of Zurich,
Switzerland. We will include patients with newly diagnosed localized prostate cancer independently
of treatment finally chosen. We will acquire clinical data including quality of life and lifestyle,
prostate tissue specimen as well as further biological samples (blood and urine) before, during and
after treatment for setup of a bio-bank. Assessment of these data and samples in the follow up will
be done during routine controls. Study duration will be at least ten years. Influence of treatment
on morbidity and mortality, including changes in quality of life, will be identified and an evaluation
of biomarkers will be performed. Further we intend to set up a bio-bank containing blood and urine
samples providing research of various natures around prostate cancer in the future.
Discussion: We presume that this study will provide answers to pertinent questions concerning
prognosis and outcomes of men with localised prostate cancer.
Background
Prostate cancer is the most frequent newly diagnosed
malignancy in men in the Western world, and the second
leading cancer-related cause of death. In the USA, 219,000
newly diagnosed cases and 27,000 related deaths have
been predicted for 2007 [1]. This data is more clearly
described by Walsh [2], who noted that approximately 1
of 6 men in the USA were diagnosed with prostate cancer,
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while 1 of 34 died from the cancer. Prostate cancer inci-
dence rates continue to increase, although at a slower rate
than reported in the early 1990s and prior. Nevertheless,
given that the population in the developed world is rap-
idly aging, the percentage of cases of the disease is
expected to rise dramatically. Taking this data into
account, the medical and socio-economic consequences
of prostate cancer are difficult to estimate.
Despite intensive research over the last several decades,
many questions, particularly those concerning early diag-
nosis and the choice of optimal treatment for each indi-
vidual patient, still remain unanswered. There are two
main problems today.
PSA (prostate specific antigen) screening increases the
number of patients suspected of cancer due to the high
number of false positive results. Subsequent needle biop-
sies lead to over-diagnosis and lead to the detection of
indolent cancers which would not have affected men in
their lifetime [3-6]. Two trails are ongoing investigating
the potential benefit due to PSA screening, completion is
expected within the next five years [7,8]. Already now
some authors questioned the clinical value of these stud-
ies. They stated that "it is uncertain whether these trials
will have sufficient power to address the primary end
point of reductions in deaths from cancer, because PSA
screening of the control groups may occur outside these
studies and definitive treatment with surgery or radiation
therapy is not mandated [2]."
The second problem concerns the selection of appropriate
treatment. Adequate choice is difficult because the natural
course of disease is often unknown and both patient and
clinician face the challenging decision whether active
treatment is justified. Indeed, some studies showed a
reduction in mortality [9-11]. However, identification
which of the available treatments is best for an individual
patient remains controversial, particularly because quality
of life data are only limited available. Trials in this field
are currently in progress. The Veterans Affairs Prostate
Cancer Intervention vs. Observation (PIVOT) trial com-
pares radical prostatectomy versus observation in 731
men and will complete the follow-up in 2009. The ongo-
ing UK Prostate Testing for Cancer and Treatment Study
(ProtecT) will randomize men with prostate cancer to
receive radiation, undergo radical prostatectomy, or
remain in observation; this trial is nested within a supe-
rior PSA screening trial, and study accrual is estimated to
be completed in 2008.
The goal in treating patients with localized prostate cancer
is a curative one and includes minimizing adverse effects
to preserve an adequate quality of life. Better understand-
ing on how the quality of life is affected depending on the
treatment modality – surgery, radiation, active surveil-
lance or even a palliative transurethral resection of the
prostate (TUR-P) – would be a first, important step by
assisting patients in deciding which treatment to choose.
An improvement in the knowledge concerning prognosis
would be a further, mostly important step. Here, the
development of prognostic biomarkers that indicate the
future course of the illness is a promising approach with
potential and the focus of much attention. A further topic
of interest concerning the prognosis of prostate cancer
and prostate cancer survivors is the influence of lifestyle
factors, such as nutrition and physical activity. Patients
cured from cancer die of non-cancer causes at a higher rate
than the general population and co-morbid conditions
are probably the result of cancer treatment, genetic predis-
position and lifestyle factors [12]. Increasing the knowl-
edge concerning these topics could be of precious help in
optimizing treatment outcome.
The purpose of this paper is to describe the rationale, the
methodology and the design of a new cohort study. With
this study we intend to increase the knowledge on optimal
and individualized treatments of men with localized pros-
tate cancer. We believe that its findings will contribute to
a better quality of recommendations of physicians at the
doctor patient encounter. Moreover, our genetics research
branch will provide new insights in pathophysiology of
prostate cancer and will have the potential to guide fur-
ther clinical research particularly in prognostic testing.
Methods/Design
Study design
This is a prospective, multi-center cohort study with
observational character concerning outcome. We will
acquire clinical data including quality of life and lifestyle,
prostate tissue specimen as well as further biological sam-
ples (blood and urine) before, during and after treatment
for setup of a bio-bank.
Study location
We set up this study within the Canton of Zurich, Switzer-
land. An expansion to a national or even international
study is possible and intended.
Partners
￿ Urological, Pathological and Radio-Oncological Units
and Departments of the University Hospital of Zurich, the
Cantonal Hospital of Winterthur and the City Hospital of
Zurich.
￿ Cancer Registry of the Canton of Zurich.
￿ Department of Clinical Chemistry of the University
Hospital of Zurich.BMC Urology 2008, 8:9 http://www.biomedcentral.com/1471-2490/8/9
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￿ Horten Center for patient orientated research and
knowledge transfer of the University of Zurich.
Study population
All men with newly diagnosed localized prostate cancer
within the participating urological clinics are principally
candidates for study participation. Treatment finally cho-
sen is independent of study participation and vice versa.
Exclusion criteria are unwillingness to sign the informed
consent, an expected survival less than 6 month and refer-
ral to the participating urological clinics only for treat-
ment due to intricate data and sample collection.
Study sample size and duration
We performed a sample size calculation for survival end-
points based on the recommendation of Dupont and
Plummer [13]. We have set the alpha error at 0.05 and the
beta error at 0.2 and assumed a median survival time in
the control group of 15 years. We specified a hazard ratio
of the control group relative to the experimental group of
1.2, an accrual time during which patients are recruited of
ten years and no additional follow-up time after end of
recruitment. Since we are interested in various endpoints
we chose an extreme ratio of control to experimental
patients of 5 to be on the safe side. Based on these
assumptions the required sample size is 1545. Given the
size of the catchment's area we anticipate to include about
two hundred new patients annually which lead to a suffi-
cient number of patients to perform analyses after the end
of the recruitment period.
Procedure
We will recruit patients during urological consultations
and after diagnosis of localized prostate cancer. Men who
meet the inclusion criteria will receive detailed informa-
tion about the study. In particular, the aims, methods and
intension of setup a bio-bank will be fully explained and
written informed consent will be obtained. Data and sam-
ples (prostate tissue, blood and urine) will be acquired
during the routine consultation before, during and after
the treatment. The follow up point of times are usually
three, six and twelve month after treatment, then annu-
ally. Assistance by study nurses will ensure a mostly com-
plete data acquisition. An overview of the study flow
during the first three years is illustrated in figure 1. Unex-
pected events between the routine controls will be
recorded and followed. Within the quality control all
acquired data will become controlled before input into
the central data base will take place. A reversible anonymi-
zation for all samples belonging to the bio-bank will be
performed. In a preliminary phase of the study we will
translate and validate the EPIC (Expanded Prostate Cancer
Index Composite) questionnaire into German language
to have a mostly precise instrument for assessing disease
specific quality of life and especially changes in quality of
life.
Kind of collected data and samples
￿ Clinical data including quality of life and lifestyle fac-
tors. For general quality of life assessment we use SF-36v2
questionnaire and a "Feeling Thermometer", a valid and
reliable global estimate of health-related quality of life.
For prostate cancer specific quality of life we will use the
EPIC questionnaire (Expanded Prostate cancer Index
Composite) and the IPSS (International Prostate Symp-
toms Score). In a preliminary phase of the study we will
perform a translation and validation of the EPIC ques-
tionnaire into German language.
￿ Prostate needle biopsy cores are already available due to
preceded diagnosis and need only a special labeling. In
case of prostatectomy as final treatment the whole organ
will be stored, partly as formalin fixed and paraffin
embedded specimen in the corresponding pathology unit
of the hospital, where treatment is performed (multi-
center storage), partly a shock frozen specimen in the cen-
tral bio-bank of the Department of Pathology of the Uni-
versity Hospital of Zurich. The same procedure will be
performed in case of repeated prostate needle biopsy.
￿ For the bio-bank we will acquire further one tube of
whole blood, one tube of heparin full blood and two
tubes of EDTA full blood, all of them as venous blood; fur-
ther about 40 ml of native midstream urine. After ano-
nymization these samples will be immediately send to the
Clinical Chemistry of the University Hospital of Zurich,
where aliquotation, DNA extraction, freezing and storage
will take place.
Outcome measures (baseline and follow up)
Data and samples acquired at diagnosis and before treat-
ment belong to the baseline data. Data and samples
acquired during the follow up and after the treatment
belong to the follow up data. With exception of active sur-
veillance as treatment or in case of suspicion of cancer
recurrence, during the follow up no prostate tissue will be
acquired routinely, whereas the clinical data and blood
and urine samples for the bio-bank will be acquired at all
the visits.
Objectives
￿ To describe epidemiologic aspects of patients with
newly diagnosed localized prostate cancer; in particular,
to evaluate survival, functional outcomes, quality of life
and life style in the context of treatment modality, prog-
nosis and other clinical information.
￿ To assess the clinical relevance of recently proposed
biomarkers.BMC Urology 2008, 8:9 http://www.biomedcentral.com/1471-2490/8/9
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￿ To develop individualized, science-based treatment rec-
ommendations for patients with localized prostate cancer.
￿ To link results from basic science to applied clinical
research. For example, the study setup allows the investi-
gation of promising prognostic genetic and post-genetic
markers in a realistic clinical context and facilitates the
translation of basic scientific discoveries into clinical prac-
tice and patient care.
￿ To provide a research platform for future diagnostic and
prognostic markers using the systematically collected set
of tissues and body fluids.
￿ To generate a German version of the EPIC questionnaire
to get a validated instrument for assessment of quality of
life in prostate cancer patients available for German
speaking countries.
Study flow (the first three years) Figure 1
Study flow (the first three years).BMC Urology 2008, 8:9 http://www.biomedcentral.com/1471-2490/8/9
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Safety monitoring and adverse events
Any unexpected and/or adverse events will be recorded
and followed until they have abated or until a stable situ-
ation has been reached. Treatments or interactions may
necessary due to such events will take place within the
urological or general physician's consultation.
Ethics
This cohort study will be performed in accordance to the
World Medical Association Declaration of Helsinki [14]
and the guidelines of the Swiss Academy of Medical Sci-
ences concerning scientific research involving human
beings [15] and bio-banks [16] and will seek approval by
the Ethical Committee of the Canton of Zurich. Further,
all handling of personal data will strictly comply with the
federal law of data protection of Switzerland (Bundesges-
etz über den Datenschutz (DSG) vom 19. Juni 1992).
Statistical analysis
Epidemiologic data and patients' descriptives available on
continuous scales will be presented with medians, inter-
quartile ranges or means and standard deviations as
appropriate. Categorical data will be presented as rates
and percentages.
Association of individual (independent) variables on the
outcome variables will be reported using correlation coef-
ficients. Results from univariate analysis will inform mul-
tivariate modeling.
Assessment of causal associations will be performed using
multivariate models including potential confounders
along with the independent variables of interest. Prognos-
tic scores will be built using either multivariate logistic
regression analysis or Cox proportional hazard models.
Models will be validated in cross samples. Calibration and
discrimination of the cross-validated prognostic instru-
ments will be assessed using the Brier Score.
Discussion
This paper describes the rational, methodology and
design of a prospective, multi-center cohort study within
the Canton of Zurich including patients with localized
prostate cancer independent of treatment finally chosen.
We intend to set up a prospectively acquired clinical data-
base including quality of life data and lifestyle factors with
corresponding prostate tissue specimens (biopsy cores
and/or whole organ, dependent of treatment finally cho-
sen) and further bio-samples (blood and urine).
Based on the results we will identify treatment specific
influences on quality of life and formulate appropriate
treatment recommendations. Examination of biomarkers
will contribute to a better understanding of the underly-
ing biological mechanisms and will guide the develop-
ment of new diagnostic and prognostic algorithms.
Therefore this study will help to improve decision-mak-
ing. It will help patients weighing the pros and cons of var-
ious treatment modalities and it will help physicians to
inform their patients adequately.
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